Clinical Trial Update: Aprepitant or Ondansetron in Treating Nausea and Vomiting Caused By Opioids in Patients With Cancer [NA]

View source ↗

Summary

Clinical trial evaluating Aprepitant and Ondansetron for opioid-induced nausea and vomiting in cancer patients; the study was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leukemia
• Lymphoma
• Multiple Myeloma
• Myelodysplastic Syndromes
• Myeloproliferative Neoplasms

Drugs mentioned

• Aprepitant (aprepitant)
• Ondansetron (ondansetron)

Snippet

Sponsor: Vanderbilt-Ingram Cancer Center | Conditions: Myeloproliferative Disorders, Leukemia | NA | Status: WITHDRAWN